May 3, 2018 - By Ira Colvard

It was reported a decrease on VIA PHARMACEUTICALS INC (OTCMKTS:VIAP)’s shorted shares with 96.15%. It was issued in May by FINRA the 100 shorted shares on VIAP. Previously was reported down change of 96.15% from 2,600 shares.

$0.015 was the last price.It’s since May 3, 2017 and is 0.00% down. VIAP underperformed by 11.55% the S&P 500.

VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases.The firm is worth $308,370. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes.Currently it has negative earnings. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: